Literature DB >> 6275811

Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.

J M Kane, A Rifkin, F Quitkin, D Nayak, J Ramos-Lorenzi.   

Abstract

Twenty-eight patients who had recently recovered from an acute-onset, first-episode schizophrenic illness were randomly given fluphenazine hydrochloride or decanoate or placebo for a one-year period in a double-blind study. Seven of 17 patients(14%) receiving placebo experienced a psychotic relapse, whereas none of 11 drug-treated patients experienced a relapse. Eighteen (69%) of the 26 patients available for follow-up (mean interval, 3.5 years) experienced a second psychotic relapse either during the study or afterward, and 50% (14/28) of the original sample experienced a third episode.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6275811     DOI: 10.1001/archpsyc.1982.04290010048009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  34 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

3.  Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis.

Authors:  Jadon R Webb; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Robert K Heinssen; Larry J Seidman; Sarah I Tarbox; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Scott W Woods
Journal:  Schizophr Bull       Date:  2015-09       Impact factor: 9.306

4.  One year outcome in first episode schizophrenia. Predictors of relapse.

Authors:  Alp Uçok; Aslihan Polat; Sibel Cakir; Aysun Genç
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-18       Impact factor: 5.270

Review 5.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

Review 6.  Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis.

Authors:  Mario Alvarez-Jiménez; Alexandra G Parker; Sarah E Hetrick; Patrick D McGorry; John F Gleeson
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 7.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 8.  Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.

Authors:  M Alvarez-Jimenez; B O'Donoghue; A Thompson; J F Gleeson; S Bendall; C Gonzalez-Blanch; E Killackey; L Wunderink; P D McGorry
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 9.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

10.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.

Authors:  Eric Y H Chen; Christy L M Hui; May M L Lam; Cindy P Y Chiu; C W Law; Dicky W S Chung; Steve Tso; Edwin P F Pang; K T Chan; Y C Wong; Flora Y M Mo; Kathy P M Chan; T J Yao; S F Hung; William G Honer
Journal:  BMJ       Date:  2010-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.